# Regional blood flow signatures of opioidergic modulation of ketamine in major depressive disorder: a randomised crossover study

Luke A. Jelen[1,2], Owen O'Daly[1], Fernando O. Zelaya[1], James M. Stone[3,4], Allan H. Young[1,2,5], Mitul A. Mehta[1]

1. Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK.
2. South London and Maudsley NHS Foundation Trust, London, UK
3. Brighton and Sussex Medical School (BSMS), University of Sussex, Brighton, UK.
4. Sussex Partnership NHS Foundation Trust, West Sussex, UK
5. Imperial College London, London, UK

Corresponding author: luke.jelen@kcl.ac.uk

**ORCiDs**
Jelen, LA: orcid.org/0000-0001-6398-5239
O'Daly O: orcid.org/0000-0001-5690-1252
Zelaya F: orcid.org/0000-0002-9525-1560
Stone, JM: orchid.org/0000-0003-3051-0135
Young, AH: orcid.org/0000-0003-2291-6952
Mehta, M: orcid.org/0000-0003-1152-5323

# Abstract:

**Importance:** Accumulating evidence suggests that the opioid system may modulate ketamine's rapid antidepressant effects. Ketamine acutely increases regional and global cerebral blood flow (CBF), yet opioid system influence on these changes remains unclear.

**Objective:** To investigate how opioid system modulation via naltrexone affects ketamine-induced CBF changes in individuals with major depressive disorder (MDD) and to explore the relationship between CBF changes and receptor density profiles.

**Design:** Randomised, double-blind, crossover study.

**Setting:** Single-site clinical research setting.

**Participants:** Twenty-six adults (18-50 years) diagnosed with MDD, all exhibiting inadequate response to at least two prior antidepressant treatments (medication and/or psychotherapy).

**Interventions:** Participants received either oral naltrexone (50 mg) or placebo, followed by intravenous ketamine (0.5 mg/kg over 40 minutes) during 3D pseudo-Continuous Arterial Spin Labelling (3D-pCASL) MRI.

**Main Outcome(s) and Measure(s):** Main outcomes were CBF changes, assessed using 3D-pCASL MRI, and their relationship with subjective effects (Clinician-Administered Dissociative States Scale [CADSS] and Psychotomimetic States Inventory [PSI]) and clinical outcomes (Montgomery-Åsberg Depression Rating Scale [MADRS] and Quick Inventory of Depressive Symptomatology Self-Report [QIDS-SR]). Exploratory outcomes included correlations between CBF changes and receptor density profiles (MOR, KOR, NMDA, mGluR5, GABAA, and GABAAα5).

**Results:** Ketamine significantly increased CBF in the subgenual, pregenual, and dorsal anterior cingulate cortices ($p < 0.05$, FWE-corrected), effects not attenuated by naltrexone. Under placebo pretreatment, CBF changes after ketamine in the pregenual anterior cingulate were associated with immediate subjective effects (PSI-delusional: $r = 0.56$, $p = 0.004$; PSI-perceptual distortion: $r = 0.64$, $p < 0.001$), and baseline CBF in the subgenual anterior cingulate cortex predicted day-one antidepressant response (MADRS: $r = 0.6$, $p = 0.002$; QIDS-SR: $r = 0.67$, $p < 0.001$). Naltrexone pretreatment disrupted these predictive relationships. Ketamine-induced CBF changes correlated with MOR, and mGluR5 receptor profiles, while naltrexone's interaction was linked to MOR and GABAAα5 (corrected for spatial autocorrelation, pSA-corr $< 0.05$).

**Conclusions and Relevance:** This study demonstrates ketamine's effects on CBF in MDD are influenced by complex interactions between glutamatergic, opioidergic, and GABAergic systems. These findings provide mechanistic insights with potential implications for optimising ketamine-based treatments.

**Registration:** ClinicalTrials.gov Identifier: NCT04977674

# Introduction

At subanaesthetic doses, ketamine can produce rapid reductions in depressive symptoms and suicidal ideation, including in individuals with treatment-resistant depression (TRD) (1,2). Neuroimaging studies have explored ketamine's effects on brain structure, function, connectivity, neurochemistry, and metabolism, aiming to elucidate its therapeutic mechanisms (3). Most of the functional studies have employed blood oxygen-level-dependent (BOLD) MRI, using both resting-state and task-based paradigms (4–7). These studies consistently report alterations in brain activity and network functioning, but the relationship between these changes and symptom improvement, as well as the contributions of underlying neurotransmitter systems, remains unclear.

In addition to its primary action as an uncompetitive NMDA receptor antagonist, ketamine also modulates the opioid system (8,9). Preclinical and clinical evidence suggests that opioid system activation contributes to ketamine's rapid antidepressant effects (9–18). However, this relationship is not consistently observed across all studies (19–21). Understanding how opioid mechanisms influence ketamine's effects on brain activity and their relationship to clinical outcomes is crucial for clarifying its mechanism of action.

One fundamental aspect of ketamine's neurovascular effects is its impact on regional cerebral blood flow (rCBF), which may be mediated by both neurovascular coupling and direct vascular effects (22,23). While BOLD imaging indirectly reflects changes in brain activity through changes in CBF and in cerebral metabolic rate of oxygen consumption ($CMRO_2$) (24), arterial spin labelling (ASL) provides direct, quantitative measures of rCBF without ionising radiation or contrast agents (25). ASL has been used to examine the acute effects of psychoactive compounds, including ketamine (26), as well as opioid agonists and antagonists (27).

ASL and PET studies consistently show ketamine-induced rCBF increases in prefrontal, orbitofrontal, anterior cingulate, insular, and subcortical regions including the thalamus, caudate, putamen, and hippocampus (26,28–33). However, the relationship between these rCBF changes and antidepressant response is less consistent. Prior ASL studies in TRD patients have reported variable rCBF alterations following ketamine, with some studies associating these changes with clinical improvement (34–36).

While the effects of ketamine on rCBF have been characterised during intravenous (IV) administration in healthy individuals (26,28), no published studies have examined these effects in MDD patients during acute IV administration. Furthermore, the impact of opioid antagonism on ketamine-induced rCBF changes has not been tested in any population.

In this randomised, double-blind, crossover study, participants with MDD received two separate IV ketamine infusions during neuroimaging, each preceded by either the opioid antagonist naltrexone or placebo. Our primary neuroimaging outcome, previously reported (9), demonstrated that naltrexone attenuated the acute ketamine-induced increase in glutamate+glutamine (Glx) to total N-acetylaspartate (tNAA) ratio and the reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores on day 1 post-infusion. Here, we focus on the ASL outcomes, examining how naltrexone modulated ketamine's effects on rCBF. We hypothesised that ketamine would increase rCBF in regions implicated in emotional processing, including the subgenual, pregenual, and dorsal anterior cingulate cortex (sgACC, pgACC, dACC), as well as the thalamus, and that naltrexone would attenuate this effect (Clinicaltrials.gov: NCT04977674). Additionally, we explored the spatial relationship between ketamine-induced rCBF changes and receptor density profiles to better understand the involvement of underlying neurotransmitter systems.

# Methods

## Study Design and Procedures

Ethical approval was obtained from the London – City & East Research Ethics Committee (Reference: 21/LO/0334) and all participants provided written informed consent (ClinicalTrials.gov registration: NCT04977674).

Participants completed two study visits, each involving a double-blind oral pretreatment (naltrexone 50 mg or placebo, ascorbic acid 50 mg), administered 1 hour before a 40-minute IV ketamine infusion (0.5 mg/kg) during MRI. The two visits were separated by a 2–4-week washout period (**Figure 1A**). Pretreatment order randomisation was computer-generated using block randomisation (block size: 4) stratified by sex, ensuring balanced allocation. Pharmacy staff masked the identity of treatments by over-encapsulating both placebo and naltrexone pills. During MRI scanning, participants were continuously monitored by a study physician, with real-time assessment of respiration, pulse oximetry, and vital signs to ensure safety throughout the infusion. 3D pseudo-Continuous Arterial Spin Labelling (3D-pCASL) data were acquired twice per visit: at baseline (pre-ketamine administration) and during the final 10 minutes of the ketamine infusion (**Figure 1B**).

## Participants

Participant details have been previously reported (9). Briefly, 26 adults (18-50 years) with MDD diagnosed according to DSM-5 completed both study arms. Inclusion required a Hamilton Depression Rating Scale (HAM-D) score of at least 18 and prior inadequate response to two or more antidepressants (minimum effective dose for ≥6 weeks) or one antidepressant and a course of evidence-based psychotherapy. Regular antidepressants (≥4 weeks) were permitted, except monoamine oxidase inhibitors (MAOIs). Exclusion criteria included pregnancy, breastfeeding, schizophrenia, schizoaffective or bipolar disorder, current substance dependence, high suicide risk, prior nonresponse or intolerance to ketamine, uncontrolled medical illnesses, and MRI contraindications. Complete ASL data sets were available for 25 participants, after data from one participant was excluded due to image artifact. See **eTable 1** for participant demographics of the included sample.

## Imaging Methods

Detailed imaging methods are provided in the **Supplementary eMethods**. Briefly, all MRI data were acquired on a 3 Tesla General Electric (GE) Discovery MR750 scanner equipped with a 32-channel head coil. Regional CBF was measured at rest using 3D-pCASL with a post-labelling delay of 2025 ms and four control-label pairs collected to derive perfusion-weighted images. A proton density (PD) image was also acquired within the same series, after the control-label pairs, using identical readout parameters. The 3D Fast Spin Echo spiral multi-shot readout had eight interleaved spiral arms and 512 points per arm. Four background suppression pulses were employed. The PD image enabled computation of CBF maps in absolute, standard physiological units (mL blood/100 g tissue/min). High-resolution T1-weighted images were obtained for structural reference and spatial normalisation of the CBF maps.

### *Image Processing*

3D-pCASL pre-processing used the ASAP (Automatic Software for ASL Processing) toolbox (37) which uses Statistical Parametric Mapping (SPM12) software. PD images were co-registered to each participant's T1-weighted image, and the resulting transformation was applied to the CBF maps. Each CBF map was then spatially normalised to MNI-152 template space, masked to exclude non-brain tissue, and spatially smoothed using a 6-mm Gaussian kernel.

### *Analysis of 3D-pCASL Data*

**Global CBF:** Global CBF values were calculated by extracting mean signal from a grey matter mask using MarsBaR (38). White matter was excluded from the analysis due to the well-established insensitivity of ASL in that tissue. A linear mixed-effects (LME) model was used to assess the main effects of ketamine, pretreatment condition (naltrexone vs. placebo), and their interaction on global CBF, with participant ID included as a random effect. Analyses were implemented using R software (version 4.2.1) with the nlme package (39).

**Region of interest (ROI):** We selected nine pre-defined regions, based on prior literature, that have been implicated in ketamine's effects: sgACC area 25 (left and right), sgACC area 32, pgACC, dACC (left and right), thalamus, hippocampus, and anterior insula (see **Supplementary eMethods** and **eFigure 1**). Mean rCBF values for each ROI were extracted, and LME models were applied to examine the main effect of ketamine and ketamine-by-naltrexone interaction,

controlling for global grey matter CBF. Multiple comparisons were corrected using the Benjamini-Hochberg method (FDR 5%) (40).

**Whole-Brain Voxel-Wise Analyses:** Whole-brain voxel-wise analyses were conducted in SPM12 using a flexible factorial design. This approach allowed for the assessment of main and interaction effects of ketamine and pretreatment condition on rCBF. Age and sex were included as covariates to account for their influence on rCBF. Finally, global-grey matter CBF was included as a covariate (i.e., global normalisation). Results without global normalisation are presented as supplementary materials. Statistical maps were thresholded at $p < 0.05$, voxel-wise (peak-level) FWE-corrected.

**Associations with Clinical and Subjective Measures:** We used partial Pearson correlations, adjusting for global CBF, to examine relationships between baseline rCBF (pre-ketamine) and day-1 changes in clinical scales (MADRS, QIDS-SR, Snaith-Hamilton Pleasure Scale (SHAPS), Temporal Experience of Pleasure Scale - Anticipatory (TEPS-A), and Temporal Experience of Pleasure Scale - Consummatory (TEPS-C)). During infusion, we computed relative CBF (rCBF／global CBF) for each ROI and correlated these against day-1 clinical change scores, adjusting for pre-infusion relative CBF. Analyses of acute subjective effects (CADSS; PSI subscales) followed the same approach for baseline and infusion rCBF. All tests were run separately under placebo and naltrexone, with Bonferroni correction across nine ROIs ($\alpha < 0.0056$). To compare placebo versus naltrexone correlations, we applied Steiger's Z-test (via r.test in the psych package in R (41,42)).

**Receptor Density and CBF Correlation Analysis:** Spatial correlations between ketamine-induced rCBF changes and receptor distributions, alongside the effect of naltrexone, were examined using publicly available PET-derived receptor maps (MOR, KOR, NMDA, mGluR5, $GABA_A$, and $GABA_A\alpha5$). To account for spatial autocorrelation, Spearman's correlations between rCBF contrast maps and receptor density maps were corrected using BrainSMASH. (43) (see **Supplementary eMethods** and **eFigure 2**). Given evidence for potential opioid, dopaminergic and serotonergic interactions in ketamine's antidepressant effects (44–46), we also analysed dopaminergic ($D_1$ and $D_2$) and serotonergic PET maps ($5HT_{1A}$, $5HT_{1B}$, $5HT_{2A}$, $5HT_4$, $5HT_6$, and 5HTT).

199 # Results

200 ## Global CBF

201 Linear mixed-effects analysis revealed a significant main effect of ketamine on global grey-
202 matter CBF ($F_{1,72} = 18.1$, $p < 0.001$), with increased CBF during infusion in both the placebo-
203 plus-ketamine (mean increase = 3.75 ± 5.01 ml/100 g/min) and naltrexone-plus-ketamine
204 (mean increase = 3.25 ± 4.25 ml/100 g/min) conditions. A significant main effect of
205 pretreatment condition was also observed ($F_{1,72} = 5.27$, $p = 0.025$), with higher overall global
206 CBF in the naltrexone condition (mean = 51.39 ± 8.31) compared to placebo (mean = 49.50 ±
207 8.88). No significant ketamine-by-pretreatment interaction was found ($F_{1,72} = 0.09$, $p = 0.76$)
208 (**Supplementary eFigure 3**).

209 ## Region of interest analyses

210 Ketamine and pretreatment condition each had significant main effects on rCBF across all nine
211 ROIs (FDR-adjusted $p < 0.05$), with increased rCBF during ketamine infusion and higher overall
212 rCBF in the naltrexone condition. No significant interaction effects were observed (**Figure 2,**
213 **Supplementary eTable 2**).

214 ## Whole-brain analysis

215 Ketamine increased rCBF in a large frontal cluster encompassing the sgACC, pgACC and dACC,
216 anterior PFC, bilateral insula, inferior frontal gyri and orbitofrontal cortex ($p < 0.05$ FWE-
217 corrected) (**Figure 3, Supplementary eTable 3**). We did not observe any significant
218 pretreatment condition or ketamine-by-pretreatment condition effects in the whole-brain
219 voxel-wise analysis. For results without global normalisation see **Supplementary eFigure 3.**

220 ## Regional CBF and clinical/subjective measure associations

221 In the placebo condition, significant positive partial correlations were observed between
222 baseline rCBF in left and right sgACC-25 and day 1 depressive symptom improvement (MADRS
223 and QIDS-SR). Lower baseline CBF predicted greater antidepressant response. These
224 associations were absent under naltrexone (**Figure 4A–C).** Steiger's Z-tests demonstrated each
225 association was significantly stronger under placebo than naltrexone: left sgACC-25–QIDS-SR

(t = 2.67, p = 0.014); right sgACC-25–MADRS (t = 2.18, p = 0.040); and right sgACC-25–QIDS-SR (t = 2.55, p = 0.018).

In the placebo condition, changes in relative pgACC rCBF during ketamine infusion were positively correlated with PSI delusional and perceptual distortion scores, whereas hippocampal rCBF changes were negatively correlated with perceptual distortion. These correlations were abolished under naltrexone (**Figure 4D–F**). Steiger's Z-tests demonstrated each association was significantly stronger under placebo than naltrexone: pgACC–PSI delusional (t = 6.12, p < 0.001), pgACC–PSI perceptual distortion (t = 8.46, p < 0.001), and hippocampus–PSI perceptual distortion (t = –5.86, p < 0.001).

A positive correlation was also found between baseline left sgACC-25 rCBF and PSI anhedonia under placebo (r = 0.625, p = 0.001), but not naltrexone (r = 0.322, p = 0.125). Conversely, baseline thalamus rCBF was negatively correlated with PSI paranoia under naltrexone (r = –0.562, p = 0.004), but not placebo (r = –0.322, p = 0.125). However, these correlations did not differ significantly between conditions (t = 1.59, p = 0.13; t = 1.88, p = 0.073).

ΔCBF and receptor density profile associations

Spatial correlation analyses showed a significant association between ketamine-induced ΔCBF and MOR distribution (r = 0.491 $p_{SA\text{-}corr}$ = 0.0289), and a weaker but significant correlation with mGluR5 distribution (r = 0.290, $p_{SA\text{-}corr}$ = 0.0286) (**Figure 5 and Supplementary eTable 4**). For the ketamine x naltrexone interaction contrast, significant correlations were observed with MOR and $GABA_A\alpha5$ receptor distributions (r = 0.530, $p_{SA\text{-}corr}$ = 0.0233 and r = 0.531, $p_{SA\text{-}corr}$ = 0.0013 respectively). No significant spatial correlations were found with KOR, NMDA, or $GABA_A$ receptor maps.

See **Supplementary eFigure 4 and eTable 5** for dopaminergic and serotonergic receptor density associations.

## Discussion

In this study, we used non-invasive perfusion MRI to examine the neurophysiological mechanisms underlying ketamine's rapid antidepressant effects and explored the impact of opioid receptor antagonism using naltrexone. Consistent with our hypothesis, ketamine significantly increased rCBF in the sgACC, pgACC and dACC as well as the thalamus. Additional rCBF increases were observed in the bilateral insula, hippocampus, and frontal regions, including the anterior PFC, inferior frontal gyri, and orbitofrontal cortex. Contrary to our hypothesis, naltrexone did not significantly attenuate these ketamine-induced CBF changes in any focal region. Instead, naltrexone was associated with increased global CBF. ROI analyses showed that ketamine-induced rCBF changes correlated with subjective effects and that baseline rCBF predicted next-day reductions in depression ratings. These relationships were abolished by naltrexone pretreatment. Finally, we found significant relationships between the spatial distribution of perfusion changes induced by ketamine and opioidergic, and glutamatergic systems (MOR and mGluR5), and between the spatial distribution of the naltrexone interaction effect on ketamine induced CBF changes and opioidergic and GABAergic systems (MOR and $GABA_A\alpha5$).

Our findings align with previous studies in healthy volunteers, where ketamine has been shown to increase CBF in similar regions, including anterior and subgenual areas of the cingulate, thalamus, and hippocampus (26,28,29,31,32). These regions are consistently implicated in the pathophysiology of major depression and in the therapeutic effects of antidepressant treatments (47–50). Specifically, hyperactivity in the sgACC is a well-established marker of depression, and successful treatment is often associated with normalisation of this region's activity (49,51–53). Our observation that lower baseline relative CBF in the sgACC-25 predicted greater antidepressant response to ketamine the next day (under the placebo condition) aligns with other studies showing relative hyperactivity in the sgACC (area 24, 25, 32) often predicts non-response to both drug and psychological treatments (54–56) and suggests that rCBF in this region could serve as a predictive biomarker for treatment outcomes.

We observed that under placebo pretreatment, ketamine-induced rCBF changes in the pgACC and hippocampus were associated with acute subjective effects, including perceptual

280 distortions and delusional thoughts. Notably, naltrexone pretreatment abolished these
281 relationships, as well as the association between baseline sgACC-25 rCBF and delayed (24-
282 hour) antidepressant effects. These findings suggest that the acute and delayed effects of
283 ketamine may involve distinct neural circuits, both modulated by opioidergic systems. This
284 differential mediation may help explain the inconsistent relationship between ketamine's
285 immediate subjective effects and its longer-lasting antidepressant response (57).

286 Unexpectedly, naltrexone was associated with a global increase in CBF, but without significant
287 focal effects. This finding could indicate a diffuse modulatory impact of naltrexone on
288 neurovascular function, potentially through direct effects on cerebral vasculature or
289 interference with endorphinergic mechanisms in CBF regulation (58–60). Prior studies using
290 naloxone did not demonstrate similar effects (27), although methodological differences (e.g.
291 partial brain coverage) or participant characteristics (healthy volunteers and patients with
292 depression) may explain this discrepancy.

293 Our exploratory analysis revealed that the spatial distribution of ketamine-induced rCBF
294 changes was significantly correlated with receptor density maps for MOR and mGluR5
295 receptors and the effect of naltrexone on the spatial distribution of ketamine induced CBF
296 changes with MOR and GABAAα5 receptor maps. The absence of a correlation with NMDA
297 receptor density (despite ketamine's established role as an NMDA receptor antagonist) may
298 reflect limitations in the NMDA PET tracer used ([18F]GE-179), which has shown limited
299 specificity (61). The association between ketamine's rCBF effects and mGluR5 is consistent
300 with prior evidence showing that ketamine can reduce mGluR5 availability in humans,
301 potentially reflecting downstream glutamatergic modulation (62,63). Notably, the significant
302 association with GABAAα5 and the ketamine-by-naltrexone interaction highlights a potential
303 modulatory role of GABAergic inhibition in opioid–glutamate crosstalk. $GABA_A$α5 subunit
304 receptors, located in cortical and limbic brain regions associated with depression (64),
305 facilitate inhibition via SST-expressing interneurons on dendrite-targeting projections (65,66).
306 GABAergic interneurons have been identified as the cellular trigger for ketamine's rapid
307 antidepressant actions, with evidence that GluN2B subunit deletion in SST interneurons blocks
308 ketamine's behavioural efficacy in animal models (67). MORs are also located on GABAergic
309 interneurons (68,69). It has been shown that MOR expression, specifically on SST interneurons
310 is necessary for the acute and antidepressant-like responses to the atypical antidepressant

311 tianeptine (70). Through this circuit, activating MORs on SST interneurons can decrease their
312 activity, providing an additional mechanism that could contribute to the disinhibition of
313 glutamatergic pyramidal neurons.

314 Taken together, our findings support a speculative model whereby ketamine acts to inhibit SST
315 interneurons, both via NMDA antagonism and via direct or indirect effects on MORs, also
316 located on SST interneurons. This would lead to the disinhibition of pyramidal cells and an
317 acute glutamate burst (9). In the presence of naltrexone, direct MOR antagonist effects on the
318 SST interneurons would act to increase GABA release onto pyramidal cells dendrites, thereby
319 increasing the inhibitory balance and attenuating ketamine-induced increases in
320 glutamatergic activity (**Supplementary eFigure 5**). This is a selective model and the full range
321 of circuits and neurotransmitter systems at play is much more elaborate and multifaceted.
322 Indeed, our supplementary analysis also uncovered relationships between serotonergic
323 receptor density maps and the spatial distribution of ketamine CBF effects (5-HT$1_b$ and 5-HT$_{2a}$)
324 and ketamine – naltrexone interaction effects with dopaminergic and serotonergic maps ($D_1$,
325 $D_2$, 5-HT$_{1a}$, 5-HT$_4$ and 5-HTT) (**Supplementary eFigure 4 and eTable 5**). This further supports
326 the view that opioid modulation is not an isolated effect but involves interactions with other
327 neurotransmitter systems, including glutamatergic, GABAergic, dopaminergic, and
328 serotonergic, all implicated in ketamine's antidepressant actions (1,45).

329 Strengths and Limitations

330 This study is the first to explore the impact of opioid receptor antagonism on acute CBF
331 changes induced by ketamine in patients with MDD using a randomised, double-blind,
332 crossover design. The use of 3D-pCASL imaging provided quantitative, non-invasive
333 measurements of CBF, enhancing the reliability of our findings. Our exploratory analysis
334 linking rCBF changes with receptor density profiles offers novel insights into the potential
335 neurotransmitter systems involved in ketamine's effects.

336 Several limitations should be acknowledged. Without a healthy control group, we are limited
337 to determine whether the observed findings are specific to individuals with MDD. The lack of
338 a placebo infusion arm also prevents us from conclusively attributing observed CBF changes
339 to ketamine rather than non-specific effects. While age and sex were included as covariates,

340 other factors like BMI and concurrent medications were not controlled in our within-subject
341 analyses. Additionally, receptor associations were based on PET maps from healthy
342 populations, which may not reflect distributions in MDD. Future studies using individualised
343 receptor mapping may provide greater precision.

## 344 Conclusion

345 This study demonstrates that ketamine administration in MDD patients increases CBF in
346 regions critical for emotional processing, including the sgACC, pgACC, dACC, thalamus, insula,
347 and hippocampus. Regional baseline CBF predicted antidepressant response, while ketamine-
348 induced CBF changes were associated with acute subjective effects. However, these predictive
349 relationships were disrupted by naltrexone pretreatment. Our findings indicate that
350 ketamine's impact on brain perfusion is not solely mediated by glutamatergic mechanisms but
351 is also influenced by interactions with opioidergic and other neurotransmitter systems. The
352 spatial correlations between CBF changes and receptor density maps underscores this
353 complexity, suggesting that ketamine's effects may emerge from a dynamic interplay among
354 multiple neurotransmitter systems, including, but not limited to glutamatergic, opioidergic,
355 and GABAergic pathways.

356 Figures




357
358 **Figure 1: Study overview.** A) 26 participants with major depressive disorder (MDD) were enrolled in a within-
359 subject, randomised, crossover design. Each participant received oral placebo or naltrexone one hour before a
360 ketamine infusion (0.5 mg/kg over 40 minutes) during an MRI session at two separate visits. The two visits were
361 separated by a 2–4-week washout period. Participants were randomised into two groups: 13 participants
362 received placebo pretreatment at their first visit and naltrexone at their second; the remaining 13 participants
363 received naltrexone first, followed by placebo at the second visit. B) At each visit, participants completed pre-
364 dose clinical assessments prior to any drug administration. Oral placebo or naltrexone was administered one
365 hour before the ketamine infusion. During the MRI session, a high-resolution structural scan was followed by a
366 baseline (pre-infusion) 3D pseudo-Continuous Arterial Spin Labelling (pCASL) scan. Ketamine (0.5 mg/kg) was
367 then infused over 40 minutes while participants remained in the scanner. A second 3D-pCASL scan was acquired
368 during the final 10 minutes of the infusion. Immediately after the infusion, subjective measures were collected,
369 with participants asked to recall peak drug effects. Follow-up clinical assessments were conducted again 24 hours
370 post-infusion (Day 1).




**Figure 2: Regional CBF values and percentage change across regions of interest.** CBF values are shown for the Pre (pre-infusion) and Ketamine (during infusion) scans for each pretreatment condition (placebo and naltrexone). The thick lines represent the mean values for each condition. Panels represent the following ROIs: A) sgACC-25 (left), B) sgACC-25 (right), C) sgACC-32, D) pgACC, E) dACC (left), F) dACC (right), G) thalamus (bilateral), H) insula (bilateral), and I) hippocampus (bilateral). Boxplots to the right of each panel display the percentage change in CBF for placebo (P) and naltrexone (N) conditions. Box plot elements: Box spans the interquartile range (IQR) (25th–75th percentile), central line is the median (50th percentile), "+" marks the mean, whiskers extend to the lowest and highest values within 1.5 × IQR of the box, and values beyond that range are shown individually. Each plot shows data from participants with complete 3D-pCASL data sets (n = 25).




**Figure 3: The main effect of ketamine on CBF for the whole-brain voxel-wise analysis (with global normalisation).** Results overlaid on the SPM152 T1 template distributed with MRIcroGL The MNI z-axis is shown at the top of the figure. Statistical maps were thresholded at $p < 0.05$, voxel-wise (peak-level) FWE-corrected. The colour bar shows the t statistic.




**Figure 4: Baseline regional CBF predicts day 1 clinical measure changes and ketamine-induced regional CBF changes predict subjective measure scores for placebo pretreatment condition only.** A) Plot of relative sgACC-25 (right) CBF at baseline against day 1 MADRS change scores; B) Plot of relative sgACC-25 (right) CBF at baseline against day 1 QIDS-SR change scores; C) Plot of relative sgACC-25 (left) CBF at baseline against day 1 QIDS-SR change scores; D) Plot of relative pgACC CBF change during ketamine infusion and PSI delusional subscale scores; E) Plot of relative pgACC CBF change during ketamine infusion and PSI perceptual distortion subscale scores; F) Plot of relative Hippocampus CBF change during ketamine infusion and PSI perceptual distortion subscale scores.

388




**Figure 5. Associations between ΔCBF and receptor density profiles.** A) Main effect of ketamine under placebo (Ketamine > Pre-Ketamine) with Spearman correlations against each receptor map. B) Ketamine × Naltrexone interaction effect on CBF with Spearman correlations against each receptor map. Asterisks denote correlations significant after spatial-autocorrelation correction (* pSA-corr < 0.05) and after additional Benjamini–Hochberg FDR correction (** FDR-corr < 0.05).

## Acknowledgements

We thank all study participants, and the research nurses, radiographers, and support staff at the NIHR King's Clinical Research Facility for their invaluable assistance. This is independent research funded by a Medical Research Council Clinical Research Training Fellowship (grant number MR/T028084/1 awarded to L.A.J) and carried out at the NIHR (National Institute for Health and Care Research) Maudsley Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the Medical Research Council, the National Institute for Health and Care Research or the Department of Health and Social Care.

## Author Contributions

The study was conceptualised by L.A.J., J.M.S., A.H.Y. and M.A.M. Funding was obtained by L.A.J., J.M.S., A.H.Y. and M.A.M. Study methodology was developed by L.A.J., O.O, F.O.Z, J.M.S., A.H.Y. and M.A.M. L.A.J. led the investigation, project administration, data curation and formal analysis under the supervision of J.M.S., A.H.Y. and M.A.M. L.A.J. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The original draft was written by L.A.J., with review and editing by L.A.J., J.M.S., A.H.Y. and M.A.M. All authors have read, commented on and approved the final version of the manuscript.

## Competing Interests

**L.A.J:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **O.O:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **F.O.Z:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **J.M.S:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. **A.H.Y:** Employed by Imperial College London; Honorary Consultant South London and Maudsley NHS Foundation Trust (NHS UK). Editor of Journal of Psychopharmacology and Deputy Editor, BJPsych Open. Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Neurocentrx. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: "An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression." Principal Investigator on "The Effects of Psilocybin on Cognitive Function in Healthy Participants". Principal Investigator on "The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)". Principal Investigator on ''A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy.'' (Janssen). Principal Investigator on '' An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD).'' (Janssen). Principal Investigator on ''A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy.'' Principal Investigator on '' A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With

Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR.'' (Janssen). UK Chief Investigator for Compass; COMP006 & COMP007 studies. UK Chief Investigator for Novartis MDD study MIJ821A12201. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) EU Horizon 2020. No shareholdings in pharmaceutical companies. **M.A.M:** Has current funding from Nxera, Takeda and Lundbeck and has acted as an advisor for Boehringer Ingelheim, Neurocentrx, Quolet Pharmaceuticals and Nxera.

## References


1. Jelen LA, Stone JM. Ketamine for depression. Int Rev Psychiatry. 2021/02/12 ed. 2021 Feb 11;1–32.

2. Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. J Affect Disord. 2020 Dec 1;277:831–41.

3. Zavaliangos-Petropulu A, Al-Sharif NB, Taraku B, Leaver AM, Sahib AK, Espinoza RT, et al. Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2023 Apr 1;8(4):361–86.

4. Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacol. 2017 May;42(6):1210–9.

5. Evans JW, Szczepanik J, Brutsche N, Park LT, Nugent AC, Zarate CA Jr. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. Biol Psychiatry [Internet]. 2018/03/28 ed. 2018 Feb 15; Available from: https://www.ncbi.nlm.nih.gov/pubmed/29580569

6. Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, et al. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Mol Psychiatry. 2021;26(7):3292–301.

7. Morris LS, Costi S, Tan A, Stern ER, Charney DS, Murrough JW. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacol. 2020 May;45(6):975–81.

8. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018/06/28 ed. 2018 Jul;70(3):621–60.

9. Jelen LA, Lythgoe DJ, Stone JM, Young AH, Mehta MA. Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study. Nat Med. 2025 Jul 24;1–9.

10. Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Solis O, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry [Internet]. 2021/04/17 ed. 2021 Apr 15; Available from: https://www.ncbi.nlm.nih.gov/pubmed/33859356

11. Klein ME, Chandra J, Sheriff S, Malinow R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci U S A. 2020/01/17 ed. 2020 Feb 4;117(5):2656–62.

12. Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. Am J Psychiatry. 2018/08/30 ed. 2018 Dec 1;175(12):1205–15.

13. Di Ianni T, Ewbank SN, Levinstein MR, Azadian MM, Budinich RC, Michaelides M, et al. Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats. Nat Commun. 2024 Jan 30;15(1):893.

14. Levinstein MR, Carlton ML, Ianni TD, Ventriglia EN, Rizzo A, Gomez JL, et al. Mu opioid receptor activation mediates (S)-ketamine reinforcement in rats: implications for abuse liability. Biological Psychiatry [Internet]. 2022 Dec 24 [cited 2023 Jan 3];0(0). Available from: https://www.biologicalpsychiatryjournal.com/article/S0006-3223(22)01854-6/fulltext

15. Jiang C, DiLeone RJ, Pittenger C, Duman RS. The endogenous opioid system in the medial prefrontal cortex mediates ketamine's antidepressant-like actions. Transl Psychiatry. 2024 Feb 12;14(1):90.

16. Zhang F, Hillhouse TM, Anderson PM, Koppenhaver PO, Kegen TN, Manicka SG, et al. Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice. Pharmacol Biochem Behav. 2021/07/06 ed. 2021 Jul 2;173228.

17. Pomrenze MB, Vaillancourt S, Llorach P, Rijsketic DR, Casey AB, Gregory N, et al. Ketamine evokes acute behavioral effects via μ-opioid receptor expressing neurons of the central amygdala. Biological Psychiatry [Internet]. 2025 May 5 [cited 2025 Jun 4]; Available from: https://www.sciencedirect.com/science/article/pii/S0006322325011771

18. Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019/08/31 ed. 2019 Dec;24(12):1779–86.

19. Yoon G, Petrakis IL, Krystal JH. Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder. JAMA Psychiatry. 2019 Mar 1;76(3):337.

20. Zhang K, Hashimoto K. Lack of Opioid System in the Antidepressant Actions of Ketamine. Biol Psychiatry. 2018/12/14 ed. 2019 Mar 15;85(6):e25–7.

21. Marton T, Barnes DE, Wallace A, Woolley J. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity. Biological Psychiatry. 2019;85(15):e75–6.

22. Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature. 2010 Nov;468(7321):232–43.

23. Mervin LH, Mitricheva E, Logothetis NK, Bifone A, Bender A, Noori HR. Neurochemical underpinning of hemodynamic response to neuropsychiatric drugs: A meta- and cluster analysis of preclinical studies. J Cereb Blood Flow Metab. 2021 Apr 1;41(4):874–85.

24. Simon AB, Buxton RB. Understanding the dynamic relationship between cerebral blood flow and the BOLD signal: Implications for quantitative functional MRI. Neuroimage. 2015 Aug 1;116:158–67.

25. Petcharunpaisan S, Ramalho J, Castillo M. Arterial spin labeling in neuroimaging. World J Radiol. 2010/12/17 ed. 2010 Oct 28;2(10):384–98.

26. Pollak TA, De Simoni S, Barimani B, Zelaya FO, Stone JM, Mehta MA. Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study. Psychopharmacology (Berl). 2015/10/07 ed. 2015 Dec;232(24):4515–24.

27. Zelaya FO, Zois E, Muller-Pollard C, Lythgoe DJ, Lee S, Andrews C, et al. The response to rapid infusion of fentanyl in the human brain measured using pulsed arterial spin labelling. MAGMA. 2011/11/25 ed. 2012 Apr;25(2):163–75.

28. Bojesen KB, Andersen KA, Rasmussen SN, Baandrup L, Madsen LM, Glenthoj BY, et al. Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers. Front Psychiatry. 2018/02/23 ed. 2018;9:22.

29. Bryant JE, Frölich M, Tran S, Reid MA, Lahti AC, Kraguljac NV. Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism. Journal of Psychiatric Research. 2019 Oct 1;117:108–15.

30. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA. Effects of Noncompetitive NMDA Receptor Blockade on Anterior Cingulate Cerebral Blood Flow in Volunteers with Schizophrenia. Neuropsychopharmacol. 2005 Dec;30(12):2275–82.

31. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA. Sequential Regional Cerebral Blood Flow Brain Scans Using PET with H215O Demonstrate Ketamine Actions in CNS Dynamically. Neuropsychopharmacol. 2001 Aug;25(2):165–72.

32. Långsjö JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, et al. Effects of Subanesthetic Doses of Ketamine on Regional Cerebral Blood Flow, Oxygen Consumption, and Blood Volume in Humans. Anesthesiology. 2003 Sep 1;99(3):614–23.

33. Rowland LM, Beason-Held L, Tamminga CA, Holcomb HH. The interactive effects of ketamine and nicotine on human cerebral blood flow. Psychopharmacology. 2010 Mar 1;208(4):575–84.

34. Gärtner M, Weigand A, Meiering MS, Weigner D, Carstens L, Keicher C, et al. Region- and time- specific effects of ketamine on cerebral blood flow: a randomized controlled trial. Neuropsychopharmacol. 2023 May 25;1–7.

35. Gonzalez S, Vasavada MM, Njau S, Sahib AK, Espinoza R, Narr KL, et al. Acute changes in cerebral blood flow after single-infusion ketamine in major depression: A pilot study. Neurology, Psychiatry and Brain Research. 2020 Dec 1;38:5–11.

36. Sahib AK, Loureiro JR, Vasavada M, Kubicki A, Joshi S, Wang K, et al. Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder. Eur Neuropsychopharmacol. 2020 Apr;33:89–100.

37. Mato Abad V, García-Polo P, O'Daly O, Hernández-Tamames JA, Zelaya F. ASAP (Automatic Software for ASL Processing): A toolbox for processing Arterial Spin Labeling images. Magnetic Resonance Imaging. 2016 Apr 1;34(3):334–44.

38. Brett M, Anton JL, Valabregue R, Poline JB. Region of interest analysis using an SPM toolbox. In Sendai, Japan; 2002.

39. Pinheiro J, Bates D. nlme: Linear and Nonlinear Mixed Effects Models [Internet]. 2022. Available from: https://cran.r-project.org/web/packages/nlme/nlme.pdf

40. Feser WJ, Fingerlin TE, Strand MJ, Glueck DH. CALCULATING AVERAGE POWER FOR THE BENJAMINI-HOCHBERG PROCEDURE. J Stat Theory Appl. 2009;8(3):325–52.

41. Revelle W. psych: Procedures for Psychological, Psychometric, and Personality Research [Internet]. 2022. Available from: https://cran.r-project.org/web/packages/psych/index.html

42. Steiger JH. Testing Pattern Hypotheses On Correlation Matrices: Alternative Statistics And Some Empirical Results. Multivariate Behavioral Research. 1980 Jul 1;15(3):335–52.

43. Burt JB, Helmer M, Shinn M, Anticevic A, Murray JD. Generative modeling of brain maps with spatial autocorrelation. NeuroImage. 2020 Oct 15;220:117038.

44. Jelen LA, Stone JM, Young AH, Mehta MA. The opioid system in depression. Neurosci Biobehav Rev. 2022 Sep;140:104800.

45. Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. J Psychopharmacol. 2020/11/07 ed. 2021 Feb;35(2):109–23.

46. Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2017/10/04 ed. 2018 Jan;23(1):59–69.

47. Drevets W, Videen T, Price J, Preskorn S, Carmichael S, Raichle M. A functional anatomical study of unipolar depression. J Neurosci. 1992 Sep 1;12(9):3628–41.

48. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 2008/08/16 ed. 2008 Aug;13(8):663–81.

49. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005/03/08 ed. 2005 Mar 3;45(5):651–60.

50. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal Limbic-Cortical Function and Negative Mood: Converging PET Findings in Depression and Normal Sadness. AJP. 1999 May 1;156(5):675–82.

596 51. Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, et al. Differences in
597 brain glucose metabolism between responders to CBT and venlafaxine in a 16-week
598 randomized controlled trial. Am J Psychiatry. 2007 May;164(5):778–88.

599 52. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin
600 Invest. 2009 Apr;119(4):717–25.

601 53. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional
602 metabolic effects of fluoxetine in major depression: serial changes and relationship to
603 clinical response. Biological Psychiatry. 2000 Oct 15;48(8):830–43.

604 54. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, et al. Regional brain
605 metabolic changes in patients with major depression treated with either paroxetine or
606 interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001 Jul;58(7):631–40.

607 55. Konarski JZ, Kennedy SH, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, et al. Predictors of
608 nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in
609 major depressive disorder. J Psychiatry Neurosci. 2009 May;34(3):175–80.

610 56. McGrath CL, Kelley ME, Dunlop BW, Holtzheimer PE, Craighead WE, Mayberg HS.
611 Pretreatment brain states identify likely nonresponse to standard treatments for
612 depression. Biol Psychiatry. 2014 Oct 1;76(7):527–35.

613 57. Ballard ED, Zarate CA. The role of dissociation in ketamine's antidepressant effects. Nat
614 Commun. 2020 Dec 22;11(1):6431.

615 58. Benyó Z, Wahl M. Opiate receptor-mediated mechanisms in the regulation of cerebral
616 blood flow. Cerebrovasc Brain Metab Rev. 1996;8(4):326–57.

617 59. Sa´ndor P, De Jong W, De Wied D. Endorphinergic mechanisms in cerebral blood flow
618 autoregulation. Brain Research. 1986 Oct 29;386(1):122–9.

619 60. Turner DM, Kassell NF, Sasaki T, Comair YG, Boarini DJ, Beck DO. Effects of naloxone on
620 cerebral blood flow and metabolism in isoflurane/nitrous oxide-anesthetized dogs.
621 Neurosurgery. 1984 Jun;14(6):688–96.

622 61. Schoenberger M, Schroeder FA, Placzek MS, Carter RL, Rosen BR, Hooker JM, et al. In vivo
623 [18F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges
624 in rodents and non-human primates. ACS Chem Neurosci. 2018 Feb 21;9(2):298–305.

625 62. DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, et al. In vivo
626 ketamine-induced changes in [$^{11}$C]ABP688 binding to metabotropic glutamate receptor
627 subtype 5. Biol Psychiatry. 2015 Feb 1;77(3):266–75.

628 63. Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, et al. Ketamine-
629 induced reduction in mGluR5 availability is associated with an antidepressant response:
630 an [$^{11}$C]ABP688 and PET imaging study in depression. Mol Psychiatry. 2018 Apr
631 1;23(4):824–32.

632 64. Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and
633 Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019
634 Apr;102(1):75–90.

635 65. Fee C, Banasr M, Sibille E. Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron
636 Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives. Biological
637 Psychiatry. 2017 Oct;82(8):549–59.

638 66. Schulz JM, Knoflach F, Hernandez MC, Bischofberger J. Dendrite-targeting interneurons
639 control synaptic NMDA-receptor activation via nonlinear α5-GABAA receptors. Nature
640 Communications. 2018;9(1).

641 67. Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ, et al. GABA interneurons are the
642 cellular trigger for ketamine's rapid antidepressant actions. J Clin Invest. 2019/11/20 ed.
643 2020 Mar 2;130(3):1336–49.

644 68. Jiang C, Wang X, Le Q, Liu P, Liu C, Wang Z, et al. Morphine coordinates SST and PV
645 interneurons in the prelimbic cortex to disinhibit pyramidal neurons and enhance reward.
646 Mol Psychiatry. 2021 Apr;26(4):1178–93.

647 69. Taki K, Kaneko T, Mizuno N. A group of cortical interneurons expressing mu-opioid
648 receptor-like immunoreactivity: a double immunofluorescence study in the rat cerebral
649 cortex. Neuroscience. 2000;98(2):221–31.

650 70. Han J, Andreu V, Langreck C, Pekarskaya EA, Grinnell SG, Allain F, et al. Mu opioid receptors
651 on hippocampal GABAergic interneurons are critical for the antidepressant effects of
652 tianeptine. Neuropsychopharmacology. 2022 Jun;47(7):1387–97.

653